Oncopharmpod

Discussing the new pseudomonas exotoxin drug (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia (3rd line). Lots of supportive care measures required, surprisingly, for the pseudomonas exotoxin drug.

Celebrating World Marrow Donor Day by recapping the HSCT donation experience of your favorite podcast host.

5-FU: both its mechanisms, all its toxicities, most of its uses, and some of its history are discussed.

The debut of our mailbag (Ask OncoPharm) to give some tips to new oncology pharmacists. Then (13:10) we review the RELEVANCE study of rituximab/lenalidomide in follicular lymphoma.

It's flu shot season, so we're taking a pseudo-systematic review of influenza vaccination in patient receiving chemotherapy. Questions addressed include: How effective is influenza vaccination for cancer patients? What's the optimal timing of vaccination during chemo?

Small cell lung cancer is reviewed, including the milestone advances (chemo + RT, omitting surgery, cis/etoposide) of the past leading up to the latest advance (15:20) - FDA-approval of nivolumab in the 3rd-line setting.

Mogamulizumab-kpkc (MOAs, administration, toxicity) and its FDA-approval is discussed followed by (9:00) updates lenvatinib (a good update) and azithromycin (a bad update) in cancer patients.

We explore the origins of rituximab's dose, geek out on the NNT in DLBC, and discuss other "need to know" tidbits.

Catching up the recent FDA-approvals for iobenguane I-131 (and its myriad of precautions) and lusutrombopag.

After running through recent FDA updates (including ribociclib's approval in PRE-menopausal breast cancer patients), the newly approved ivosidenib is discussed.

Ten years ago a preplanned subgroup analysis changed the NSCLC treatment algorithms. We go back to the beginning with pemetrexed and the studies leading up to the oft-cited Scagliotti that ushered in histology-specific treatment in NSCLC.

We discuss paclitaxel, from its discovery to its uses to toxicity and their management as part of our Landmarks in #OncoPharm series. And if you really, really love this drug - you'll learn where to may homage at a historical marker in....

Our shortest Pod yet! Chemotherapy explosions and photosensitizing antineoplastics are discussed.

The newly FDA-approved BRAF & MEK inhibitors are discussed, along with their possible clinical relevance and some notable differences compared to previously available BRAF & MEK inhibitors.

Immunotherapy takes two steps forward (new FDA approvals)....and two steps backwards. These updates in #oncopharm are discussed before ending (11:45) with discussions of venetoclax's expanded approval in CLL, the bevacizumab approval almost 7 years in the making, and late-breaking information on preventing cisplatin ototoxicity.

The Landmarks in Oncology Pharmacy series returns with a review of 2 ondansetron studies from 1990, published simultaneously in NEJM.

Recapping (some) of the top stories from ASCO18 starting with breast cancer (TAILOR-Rx, PERSEPHONE, SANDPIPER, S0927); then NSCLC (11:35) with Keynote-42 & LOXO-292; then mylemoa (16:50) with a CAR-T update and a new dosing of carfilzomib; before ending (20:30) with CARMENA and PRODIGY-24's new mFOLFIRINOX data for adjuvant pancreatic cancer. Whew!

Previewing this week's ASCO annual meeting and the Plenary Sessions (briefly) and selected abstracts highlighting oncology pharmacy practice.

Avatrombopag's FDA-approval prompts discussion of both the indication and drug itself. Finally, the publication of the SELECT-D study allows us to dig deeper into the data of a DOAC vs. LMWH in cancer-associated VTE.

The release of ASCO's 2018 annual abstracts resulted in widespread media coverage of PERSEPHONE, the largest trial yet investigating 6 vs. 12 months of adjuvant trastuzumab in breast cancer. We get into the history of adjuvant trastuzumab studies and what to watch for going forward.